The Bimatoprost Ophthalmic Solution, cataloged under National Stock Number 6505-01-517-1139, is classified within Federal Supply Class 6505 (Drugs and Biologicals) of the Medical, Dental, and Veterinary Equipment group. The manufacturer of record is Allergan Inc. Government technical data includes 1 specification, cited from the U.S. Government catalog. The record lists 2 manufacturer part numbers for this item, enabling identification through both NSN and commercial part number lookups. 1 additional reference document (drawings, advisory and superseded references) is recorded in the U.S. Government catalog. Current acquisition status: Active.
| Parameter | Value |
|---|---|
| NSN | 6505-01-517-1139 |
| Primary Part Number | LUMIGAN 0.03 MG/ML |
| Item Name | Bimatoprost Ophthalmic Solution |
| FSC / FSG | 6505 / 65 — Drugs and Biologicals |
| Manufacturer | Allergan Inc |
| Status | ACTIVE |
| Functional Description | IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE, IOP, IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP-LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION; PROVIDES POWERFUL IOP REDUCTION THAT REMAINS CONSISTENT OVER TIME, BOTH IN NUMBER OF PATIENTS ACHIEVING LOW TARGET PRESSURE AND OVERALL PERCENTAGE REDUCTION |
| Acquisition Status | ACTIVE |
| DEMIL Code | DEMIL A — No Demilitarization Required |
| Hazard | Possible hazard — SDS may be required (DLA HMIC P) |
| Criticality Code | X |
| Part Number | Manufacturer |
|---|---|
| LUMIGAN 0.3 MG/ML 3 FL/3ML | Allergan (BEL) |
| LUMIGAN 0.03 MG/ML PRIMARY | Allergan Inc (USA) |
| Reference | Meaning |
|---|---|
| 1684315 | 5/9 Secondary reference Association Pharmaceutique Belge-Algemene Pharmaceutische Bond |
NSN 6505-01-517-1139 is a Bimatoprost Ophthalmic Solution, manufactured by Allergan Inc, classified under FSC 6505, Drugs and Biologicals. Status: active.
NSN 6505-01-517-1139 has 2 manufacturer part numbers on file: LUMIGAN 0.3 MG/ML 3 FL/3ML (Allergan), LUMIGAN 0.03 MG/ML (Allergan Inc).
Key specifications for LUMIGAN 0.03 MG/ML: Special Features: DOES NOT REQUIRE REFRIGERATION; AVAILABLE IN 2.5 ML AND 5 ML SIZES; HAS BEEN REPORTED TO CAUSE CHANGES TO PIGMENTED TISSUES; INCLUDING INCREASED PIGMENTATION AND GROWTH OF EYELASHES AND INCREASED PIGMENTATION OF THE IRIS AND PERIORBITAL TISSUE, EYELID, CHANGES MAY BE PERMANENT; Functional Description: IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE, IOP, IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP-LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION; PROVIDES POWERFUL IOP REDUCTION THAT REMAINS CONSISTENT OVER TIME, BOTH IN NUMBER OF PATIENTS ACHIEVING LOW TARGET PRESSURE AND OVERALL PERCENTAGE REDUCTION; Part Name Assigned by Controlling Agency: LUMIGAN, BIMATOPROST OPHTHALMIC SOLUTION, 0.03 PCT. 1 specification is documented in the U.S. Government catalog.
Possible hazard — SDS may be required (DLA HMIC P). Hazard information on this page is shown exactly as it appears in the DLA record.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-16.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-18.